Jazz Pharmaceuticals PLC $JAZZ Stake Raised by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 8.5% in the third quarter, HoldingsChannel reports. The fund owned 1,867,159 shares of the specialty pharmaceutical company’s stock after buying an additional 145,865 shares during the quarter. JPMorgan Chase & Co.’s holdings in Jazz Pharmaceuticals were worth $246,092,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Kennedy Capital Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter worth approximately $1,100,000. Wedge Capital Management L L P NC acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $27,834,000. Essex Investment Management Co. LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $2,697,000. Sequoia Financial Advisors LLC bought a new stake in Jazz Pharmaceuticals in the third quarter worth $605,000. Finally, Measured Wealth Private Client Group LLC increased its position in Jazz Pharmaceuticals by 47.1% during the second quarter. Measured Wealth Private Client Group LLC now owns 4,855 shares of the specialty pharmaceutical company’s stock worth $515,000 after buying an additional 1,554 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on JAZZ shares. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, November 17th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Wells Fargo & Company lifted their price target on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $205.67.

Jazz Pharmaceuticals Stock Up 0.5%

JAZZ opened at $169.59 on Friday. The business has a 50 day moving average of $167.83 and a 200-day moving average of $148.46. The stock has a market capitalization of $10.30 billion, a price-to-earnings ratio of -27.94, a P/E/G ratio of 0.91 and a beta of 0.26. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $182.99.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the sale, the chief accounting officer directly owned 7,012 shares in the company, valued at $1,200,454.40. This trade represents a 39.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the transaction, the senior vice president directly owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This represents a 10.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 84,398 shares of company stock valued at $14,957,430 in the last ninety days. Company insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.